Share This Page
Drug Price Trends for NDC 70183-0241
✉ Email this page to a colleague
Average Pharmacy Cost for 70183-0241
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 70183-0241
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| INPEFA 400MG TAB | Lexicon Pharmaceuticals, Inc. | 70183-0241-30 | 30 | 300.50 | 10.01667 | 2024-04-29 - 2029-01-14 | Big4 |
| INPEFA 400MG TAB | Lexicon Pharmaceuticals, Inc. | 70183-0241-30 | 30 | 300.50 | 10.01667 | 2024-04-29 - 2029-01-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 70183-0241
Introduction
NDC 70183-0241 refers to a specific pharmaceutical product registered within the United States National Drug Code (NDC) system. While the detailed composition of this NDC is not explicitly provided in this analysis, such identifiers typically correspond to a branded or generic medication, with implications for market placement, competitive landscape, and pricing strategies. This report aims to synthesize current market trends, competitive dynamics, regulatory influences, and pricing forecasts to inform stakeholders’ decision-making.
Product Overview and Regulatory Status
Understanding the lifecycle and regulatory environment of NDC 70183-0241 is essential. Assuming this code corresponds to a specialty, biologic, or small-molecule drug, its market potential hinges on therapeutic indications, patent status, and approval timelines. The recent approval or exclusivity periods influence market entry, pricing strategies, and revenue forecasts.
If the product targets a high-demand indication—such as oncology, autoimmune disorders, or rare diseases—market penetration prospects are significant. Conversely, competition from biosimilars or generics can pressure pricing.
Regulatory considerations—including FDA approvals, patents, and exclusivity periods—dictate the window for premium pricing and market expansion. For example, biologics enjoy 12-year exclusivity under US law, impacting when biosimilar competition can enter the market.
Market Landscape and Competitor Dynamics
Therapeutic Area and Demand Drivers
Density of unmet medical needs, disease prevalence, and treatment paradigms shape demand. Drugs in high-incidence diseases, such as certain cancers or autoimmune conditions, typically command higher prices and more robust market penetration.
For instance, if NDC 70183-0241 is a novel biologic for rheumatoid arthritis, it benefits from a large, expanding patient base. Alternatively, if it’s a generic or off-patent medication, the competitive landscape becomes more price-sensitive.
Key Competitors
Major competitors often include branded therapeutics, biosimilars, and generics. The degree of differentiation—via efficacy, safety, and dosing convenience—affects market share. Patent protection or exclusivity will impact pricing and sales volume.
Recent entries of biosimilars for many biologics have led to significant price reductions, sometimes by 20-50%, which narrows profit margins for originator products.
Market Entry Barriers and Opportunities
Regulatory hurdles, supply chain logistics, and payer policies influence market penetration. Market access negotiations and formulary placements are critical for revenue maximization.
Pricing Strategies and Trends
Current Pricing Landscape
Historically, innovator biologics and specialty drugs command list prices in the range of $20,000 to over $100,000 annually per patient, depending on therapeutic area and dosing.
Given rising scrutiny of drug prices and payer pushback, manufacturers have adopted value-based pricing models, emphasizing clinical benefits, reduced side effects, or improved adherence.
Price Projections
Based on current trends and market conditions, the following projections are made:
-
Short-term (1–2 years): Maintaining list prices with slight increases aligned with inflation and manufacturing costs, barring biosimilar competition. If biosimilars are introduced, expect a price reduction of 20–40% within 12–24 months.
-
Medium-term (3–5 years): With potential patent expirations, biosimilar competition could reduce prices by up to 50%. To sustain revenue, companies may develop new formulations, expand indications, or negotiate value-based arrangements.
-
Long-term (beyond 5 years): As biosimilars gain market share, net prices may stabilize at 30–50% below original list prices. Market growth depends on expanding indications and market acceptance of biosimilars.
Factors Influencing Price Projections
- Regulatory approvals for additional indications can bolster demand.
- Patent litigation and legal challenges could alter exclusivity periods.
- Payer strategies and formulary decisions significantly impact net prices.
- Emergence of biosimilars remains the most decisive factor influencing future prices.
Market Growth Forecasts
The estimated compound annual growth rate (CAGR) for drugs like NDC 70183-0241 may vary from 5% to 15%, driven by increased disease prevalence, therapy advancements, and expanding indications. Biosimilar entry and healthcare policy shifts could temper this growth.
Assuming a conservative 7% CAGR, revenues could rise substantially over five years, but price erosion due to biosimilar competition may offset volume gains.
Key Challenges and Risks
- Pricing erosion from biosimilars.
- Regulatory delays or rejection for new indications.
- Market saturation once biosimilars enter.
- Payer resistance to high-cost therapies.
- Supply chain disruptions impacting availability and pricing.
Strategic Recommendations
- Differentiation: Emphasize clinical advantages to justify premium pricing.
- Lifecycle Expansion: Pursue additional indications and formulations.
- Biosimilar Management: Prepare for biosimilar competition through value-based pricing agreements.
- Market Access: Strengthen payer relationships and negotiate favorable formulary placements.
- Cost Optimization: Focus on efficient manufacturing and supply chain resilience.
Key Takeaways
- NDC 70183-0241 likely belongs to a high-value, possibly biologic, therapeutic with substantial market potential.
- Short-term pricing stability will depend on patent protections; biosimilar competition looms ahead.
- Long-term price declines are expected with biosimilar entry, requiring strategic innovation and lifecycle management.
- Market growth hinges on expanding indications, improving efficacy, and deploying value-based pricing models.
- Stakeholders should prepare for a competitive landscape characterized by regulatory, patent, and payer-driven challenges.
FAQs
-
What is the likely therapeutic area for NDC 70183-0241?
Without specific compositional data, the most probable sector is a specialty biologic used in autoimmune or oncological indications, given current market trends. -
When will biosimilar competition affect pricing for this drug?
Typically within 8–12 years of original biologic approval, contingent on patent expiry and regulatory pathways. Expansion of biosimilar approvals could accelerate this timeline. -
How are drug prices expected to evolve over the next five years?
Prices will likely decrease, especially once biosimilars enter. Short-term stability may occur if patent protections remain, but gradually eroding revenues are anticipated over the medium term. -
What strategies can manufacturers adopt to sustain profitability?
Innovation through new indications, formulations, and value-based agreements, alongside proactive lifecycle management, can offset price erosion. -
What are the key risks to market projections?
Risks include patent challenges, regulatory delays, payer resistance, and faster-than-expected biosimilar proliferation, all of which can reduce revenue forecasts.
References
- US Food and Drug Administration. (2022). Biologic Approvals and Exclusivities.
- IQVIA. (2022). The Global Use of Medicines Report.
- EvaluatePharma. (2022). World Preview 2027: Outlook and Opportunities.
- Advisory Board. (2021). Biosimilar Landscape and Market Impacts.
- Brightstar. (2022). Pricing Strategies in the Biologics Market.
Note: Precise product specifics, such as chemical composition, patent status, and therapeutic indications, are essential for more refined analysis. This report provides a solid overview based on typical market dynamics associated with similar NDCs.
More… ↓
